Chapter 12: Post-Traumatic Stress Disorder

Post-traumatic stress disorder emerges as a complex psychiatric condition triggered by exposure to traumatic events that overwhelms an individual's capacity to cope, resulting in persistent alterations to emotional processing, cognition, and behavioral functioning. This chapter examines the diagnostic criteria distinguishing PTSD from normal stress responses, tracing historical conceptualizations of trauma-related pathology and establishing the foundation for understanding how exposure to threat fundamentally reshapes neural architecture and physiological regulation. The neurobiology of PTSD involves dysregulation across multiple brain systems, particularly heightened amygdala reactivity that amplifies threat detection, suppressed prefrontal cortex function that impairs extinction learning and emotional regulation, and altered hypothalamic-pituitary-adrenal axis activity that disrupts cortisol homeostasis and perpetuates hyperarousal. Early developmental trauma carries particular significance because it interferes with attachment formation, compromises affect regulation capacity, and generates lasting changes to neural networks that mediate stress response and emotional processing. The kindling hypothesis proposes that repeated or sequential trauma exposures progressively lower the threshold for stress response activation, increasing vulnerability to subsequent stressors and compounding psychological dysfunction. Clinical manifestations encompass intrusive re-experiencing of trauma memories, persistent avoidance of trauma-related cues, emotional numbing and detachment, and sustained hyperarousal characterized by heightened startle responses and persistent vigilance. Pharmacological interventions target specific symptom clusters through selective serotonin reuptake inhibitors that modulate emotional processing, beta-blockers that attenuate sympathetic nervous system activation and physiological fear responses, alpha-2 agonists that reduce hyperarousal and autonomic hyperactivity, and second-generation antipsychotics for managing dissociative symptoms or severe behavioral dyscontrol. Emerging neurochemical research highlights glutamate excitotoxicity and its role in perpetuating traumatic memory consolidation, alongside cortisol dysregulation that impairs stress recovery. Psychotherapy remains the primary evidence-based intervention, with exposure-based approaches facilitating emotional processing and fear extinction, cognitive behavioral therapy targeting maladaptive trauma-related cognitions, and eye movement desensitization and reprocessing mobilizing intrinsic adaptive processing mechanisms. Clinical decision-making regarding pharmacological augmentation considers symptom severity, presence of severe dissociation or panic phenomena, and psychotic manifestations requiring immediate neurochemical stabilization.